2,4-Dichloro-3-aminophenol hydrochloride | CAS:61693-43-4

We serve 2,4-Dichloro-3-aminophenol hydrochloride CAS:61693-43-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,4-Dichloro-3-aminophenol hydrochloride

Chemical Name:2,4-Dichloro-3-aminophenol hydrochloride
CAS.NO:61693-43-4
Synonyms:3-amino-2,4-dichlorophenol,hydrochloride;
Molecular Formula:C6H6Cl3NO
Molecular Weight:214.47700
 
Physical and Chemical Properties:
Boiling point:302.1oC;
Flash point:136.5oC;
 
Specification:
Appearance:Grey powder
Purity(HPLC):≥99.0%
Moisture:≤1.0%
Ash:≤1.0%
Fe content:≤100ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Hair dyes intermediate
 



Contact us for information like 2,4-Dichloro-3-aminophenol hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-amino-2,4-dichlorophenol,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-amino-2,4-dichlorophenol,hydrochloride Use and application,3-amino-2,4-dichlorophenol,hydrochloride technical grade,usp/ep/jp grade.


Related News: Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.Methyl N-cyanoethanimideate manufacturer Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.4-[6-amino-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile supplier What’s the background?2,4-Dichlorotoluene vendor The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.